Ruxolitinib therapy for myelofibrosis in Austria-Reference-Cited by-同舟云学术

Ruxolitinib therapy for myelofibrosis in Austria

Published:2018-07-24 Issue:17-18 Volume:130 Page:495-504
ISSN:0043-5325
Container-title:Wiener klinische Wochenschrift
language:en
Short-container-title:Wien Klin Wochenschr

Author:

Krauth Maria-Theresa,Burgstaller Sonja,Buxhofer-Ausch Veronika,Gastl Günther,Geissler Klaus,Keil Felix,Krippl Peter,Melchardt Thomas,Petzer Andreas,Rumpold Holger,Sliwa Thamer,Wöhrer Stefan,Wölfler Albert,Gisslinger Heinz

Funder

Medical University of Vienna

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/article/10.1007/s00508-018-1365-5/fulltext.html

Reference56 articles.

1. Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92(4):289–97.

2. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med. 2009;60:233–45.

3. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–901.

4. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–8.

5. Delhommeau F, Jeziorowska D, Marzac C, Casadevall N. Molecular aspects of myeloproliferative neoplasms. Int J Hematol. 2010;91(2):165–73.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Partial human Janus kinase 1 deficiency predominantly impairs responses to interferon gamma and intracellular control of mycobacteria;Frontiers in Immunology;2022-09-09

2. Positron emission tomography – computed tomography as a monitoring response tool in pre-fibrotic myelofibrosis: a case report;Journal of the Pakistan Medical Association;2022-02-03

3. Improvement in colorectal cancer outcomes over time is limited to patients with left-sided disease;Journal of Cancer Research and Clinical Oncology;2022-01-03

4. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis;Hematology;2021-12-27

5. Myeloproliferative and lymphoproliferative disorders: State of the art;Hematological Oncology;2019-12-27